These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 11544331

  • 1. CTA1-DD-immune stimulating complexes: a novel, rationally designed combined mucosal vaccine adjuvant effective with nanogram doses of antigen.
    Mowat AM, Donachie AM, Jägewall S, Schön K, Löwenadler B, Dalsgaard K, Kaastrup P, Lycke N.
    J Immunol; 2001 Sep 15; 167(6):3398-405. PubMed ID: 11544331
    [Abstract] [Full Text] [Related]

  • 2. From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM.
    Lycke N.
    Cell Microbiol; 2004 Jan 15; 6(1):23-32. PubMed ID: 14678328
    [Abstract] [Full Text] [Related]

  • 3. A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus.
    Eliasson DG, Helgeby A, Schön K, Nygren C, El-Bakkouri K, Fiers W, Saelens X, Lövgren KB, Nyström I, Lycke NY.
    Vaccine; 2011 May 23; 29(23):3951-61. PubMed ID: 21481325
    [Abstract] [Full Text] [Related]

  • 4. The combined CTA1-DD/ISCOM adjuvant vector promotes priming of mucosal and systemic immunity to incorporated antigens by specific targeting of B cells.
    Helgeby A, Robson NC, Donachie AM, Beackock-Sharp H, Lövgren K, Schön K, Mowat A, Lycke NY.
    J Immunol; 2006 Mar 15; 176(6):3697-706. PubMed ID: 16517738
    [Abstract] [Full Text] [Related]

  • 5. The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis.
    Andersen CS, Dietrich J, Agger EM, Lycke NY, Lövgren K, Andersen P.
    Infect Immun; 2007 Jan 15; 75(1):408-16. PubMed ID: 17074845
    [Abstract] [Full Text] [Related]

  • 6. The ADP-ribosylating CTA1-DD adjuvant enhances T cell-dependent and independent responses by direct action on B cells involving anti-apoptotic Bcl-2- and germinal center-promoting effects.
    Agren L, Sverremark E, Ekman L, Schön K, Löwenadler B, Fernandez C, Lycke N.
    J Immunol; 2000 Jun 15; 164(12):6276-86. PubMed ID: 10843681
    [Abstract] [Full Text] [Related]

  • 7. A novel concept in mucosal adjuvanticity: the CTA1-DD adjuvant is a B cell-targeted fusion protein that incorporates the enzymatically active cholera toxin A1 subunit.
    Agren L, Löwenadler B, Lycke N.
    Immunol Cell Biol; 1998 Jun 15; 76(3):280-7. PubMed ID: 9682972
    [Abstract] [Full Text] [Related]

  • 8. Subcomponent vaccine based on CTA1-DD adjuvant with incorporated UreB class II peptides stimulates protective Helicobacter pylori immunity.
    Nedrud JG, Bagheri N, Schön K, Xin W, Bergroth H, Eliasson DG, Lycke NY.
    PLoS One; 2013 Jun 15; 8(12):e83321. PubMed ID: 24391754
    [Abstract] [Full Text] [Related]

  • 9. ADP-ribosylating bacterial enzymes for the targeted control of mucosal tolerance and immunity.
    Lycke N.
    Ann N Y Acad Sci; 2004 Dec 15; 1029():193-208. PubMed ID: 15681758
    [Abstract] [Full Text] [Related]

  • 10. Induction of local innate immune responses and modulation of antigen uptake as mechanisms underlying the mucosal adjuvant properties of immune stimulating complexes (ISCOMS).
    Furrie E, Smith RE, Turner MW, Strobel S, Mowat AM.
    Vaccine; 2002 May 22; 20(17-18):2254-62. PubMed ID: 12009281
    [Abstract] [Full Text] [Related]

  • 11. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit.
    Agren LC, Ekman L, Löwenadler B, Lycke NY.
    J Immunol; 1997 Apr 15; 158(8):3936-46. PubMed ID: 9103464
    [Abstract] [Full Text] [Related]

  • 12. The B cell targeted adjuvant, CTA1-DD, exhibits potent mucosal immunoenhancing activity despite pre-existing anti-toxin immunity.
    Lycke N, Schön K.
    Vaccine; 2001 Mar 21; 19(17-19):2542-8. PubMed ID: 11257390
    [Abstract] [Full Text] [Related]

  • 13. Intranasal inoculate of influenza virus vaccine against lethal virus challenge.
    Fan X, Su Q, Qiu F, Yi Y, Shen L, Jia Z, Liang P, Zou Y, Bi S.
    Vaccine; 2018 Jul 05; 36(29):4354-4361. PubMed ID: 29880240
    [Abstract] [Full Text] [Related]

  • 14. Mast cells contribute to the mucosal adjuvant effect of CTA1-DD after IgG-complex formation.
    Fang Y, Larsson L, Mattsson J, Lycke N, Xiang Z.
    J Immunol; 2010 Sep 01; 185(5):2935-41. PubMed ID: 20675596
    [Abstract] [Full Text] [Related]

  • 15. CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization.
    Sundling C, Schön K, Mörner A, Forsell MNE, Wyatt RT, Thorstensson R, Hedestam GBK, Lycke NY.
    J Gen Virol; 2008 Dec 01; 89(Pt 12):2954-2964. PubMed ID: 19008380
    [Abstract] [Full Text] [Related]

  • 16. Induction of systemic and mucosal immune responses following immunization with somatostatin-avidin complexes incorporated into ISCOMS.
    Estrada A, Laarveld B, Li B, Redmond MJ.
    Immunol Invest; 1995 Aug 01; 24(5):819-28. PubMed ID: 8543345
    [Abstract] [Full Text] [Related]

  • 17. The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization.
    Akhiani AA, Stensson A, Schön K, Lycke N.
    Scand J Immunol; 2006 Feb 01; 63(2):97-105. PubMed ID: 16476008
    [Abstract] [Full Text] [Related]

  • 18. The B-cell targeted CTA1-DD vaccine adjuvant is highly effective at enhancing antibody as well as CTL responses.
    Lycke N.
    Curr Opin Mol Ther; 2001 Feb 01; 3(1):37-44. PubMed ID: 11249730
    [Abstract] [Full Text] [Related]

  • 19. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity.
    Agren LC, Ekman L, Löwenadler B, Nedrud JG, Lycke NY.
    J Immunol; 1999 Feb 15; 162(4):2432-40. PubMed ID: 9973526
    [Abstract] [Full Text] [Related]

  • 20. Oral vaccination with immune stimulating complexes.
    Mowat AM, Smith RE, Donachie AM, Furrie E, Grdic D, Lycke N.
    Immunol Lett; 1999 Jan 15; 65(1-2):133-40. PubMed ID: 10065639
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.